SFC Fluidics has inked a two-year deal with JDRF to develop an automated insulin delivery system that combines a continuous glucose monitor and an insulin delivery algorithm into a single disposable device.
JDRF is slated to provide funding to the medical device company as part of its Artificial Pancreas Project, which aims to accelerate the development of commercially available closed-loop systems.
There are a number of companies working to develop automated insulin delivery systems, ranging from medtech titan Medtronic (NYSE:MDT) to the California-based startup Bigfoot Biomedical. But research has shown that the size and form factor of these systems can play a big part in people’s willingness to adopt them into their daily lives, according to JDRF.
SFC plans to integrate a continuous glucose monitor with an insulin delivery system into a single pod that can be disposed of after three days.
“There has been tremendous progress in the development of CGM devices and closed loop algorithms. However, the integration of a pump, a CGM and an algorithm into a single, convenient pod that reduces the on-body burden for the patient has not been successfully addressed. We believe SFC’s unique pumping technology allows for an integrated AID system that will offer people with T1D an improved lifestyle,” CEO Anthony Cruz said in prepared remarks. “With our partnership with JDRF, we will bring new and innovative solutions to the diabetes community.”
“We are proud to be supporting SFC as part of our effort to advance the development of next-generation automated insulin delivery systems, to offer greater choice to people with T1D, and to lessen the burden of living with this disease while we search for a cure,” Jaime Giraldo, JDRF program scientist, added.
“By funding the development of miniaturized devices that are easier to wear and include algorithms for automation, it is our goal to make diabetes therapies less intrusive for those who must use them daily to live.”